Navigation Links
New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available
Date:1/14/2009

- Introducing the First and Only Non-Drowsy Allergy Medicine in a Liquid-Filled Capsule -

KENILWORTH, N.J., Jan. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announces the introduction of new CLARITIN(R) Liqui-Gels(R), the first and only non-drowsy allergy medicine in an easy-to-swallow liquid-filled capsule. Now available over-the-counter, CLARITIN(R) Liqui-Gels(R) provide powerful liquid relief for the worst allergy symptoms without causing drowsiness.

"New CLARITIN(R) Liqui-Gels(R) is the latest advancement for the 50 million Americans who suffer from allergies," said Dr. John O'Mullane, group vice president, research and development, Schering-Plough Consumer Health Care. "We are pleased to bring this innovative form to the line of non-drowsy CLARITIN(R) products." Liquid-filled capsules are extremely popular with consumers. A recent survey* found that 75 percent of consumers who use liquid-filled capsules prefer them over tablets.

Like all CLARITIN(R) products, new CLARITIN(R) Liqui-Gels(R) are available without a prescription and treat allergy symptoms such as itchy, watery eyes, sneezing and runny nose without drowsiness. CLARITIN(R) Liqui-Gels(R) are approved for adults and children ages 6 and older and can be found wherever over-the-counter products are sold.

About CLARITIN(R)

All CLARITIN(R) brand products are available without a prescription, including: CLARITIN(R) Tablets, a once-daily, full prescription strength, non-drowsy formulation; CLARITIN(R) RediTabs(R) Tablets, a novel once-daily formulation in a quickly dissolving tablet for ages 6 and older; CLARITIN(R) Liqui-Gels(R), a once-daily formulation in an easy-to-swallow liquid-filled capsule; CLARITIN-D(R) 24-hour and 12-hour Extended Release Tablets, with the decongestant pseudoephedrine, now located behind the counter; CHILDREN'S CLARITIN(R) Syrup, a liquid formulation for children ages 2 and older in grape and fruit flavors; and CHILDREN'S CLARITIN(R) Grape Chewables, a chewable tablet for children ages 2 and older.

CLARITIN(R) is the No. 1 physician-recommended and pediatrician-recommended non-drowsy over-the-counter allergy brand. The CLARITIN(R) Rx-to-OTC switch in 2002 was the largest switch ever--and the first and only for a non-drowsy antihistamine. For more information on allergies and treatment, visit www.CLARITIN.com.

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to potential market for CLARITIN Liqui-Gels. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the third quarter 2008 10-Q, filed October 29, 2008.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves Labeling Change for Non-Drowsy CLARITIN(R)
2. $1 Million Available to Help Michigans Uninsured Receive Care
3. ORSupply.com Unveils Largest Selection of Otoscopes Available Anywhere
4. Three Times More Powerful Than Fish Oil, MegaRed(TM) Omega-3 Krill Oil Now Available Nationwide
5. Guide on Blood Thinner Now Available in Spanish
6. Patients Benefit From Mobicosa, A Unique, Natural Arthritis Treatment Available At Your Chemist Shop
7. EyeSciences New Ocular Nutrition Supplements Available at CVS Stores
8. Plastic Surgery Experts Available to Comment on Face Transplant Surgery
9. North Carolina Student Loan Program for Health, Science and Mathematics Application Will Be Available December 20, 2008
10. Millennium Research Group Analyst Available to Comment on FDAs Premarket Approval Recommendation of Genzyme Biosurgerys Synvisc Single-Injection Product for the Knee
11. Trimma(TM) Now Available in the United States for People Looking for a Delicious Way to Control Their Calories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Fla. (PRWEB) , ... February 22, 2017 , ... ... is just as effective on smaller and sometimes harder to reach ones, according ... were presented at the International Stroke Conference in Houston by Ricardo A. Hanel, ...
(Date:2/22/2017)... ... 22, 2017 , ... The first-ever National Heart Valve Disease ... individuals join together to increase recognition about the risks of heart valve disease ... we mark a nationwide movement to raise awareness about a disease that has ...
(Date:2/22/2017)... ... ... A product of digesting a micronutrient found in soy may hold the key ... while others do not, a University of Pittsburgh Graduate School of Public Health-led study ... some types of “good” gut bacteria when they metabolize isoflavones (micronutrients found in dietary ...
(Date:2/22/2017)... North Carolina (PRWEB) , ... February 22, 2017 , ... ... of cats and 54% of dogs, according to the Association for Pet Obesity Prevention ... disagreed on key pet food issues such as the benefits of corn and grains, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... Patient Safety, patient advocates stress that the patient context (age, illness and life ... as reasons to mitigate their occurrence. In addition, all too often, ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... and PUNE, India , February 22, 2017 ... Market Research, titled, "Automated Radio Synthesis Modules Market: Global Opportunity ... radiosynthesis modules market was worth $20 million in 2015 and ... CAGR of 6.6% from 2016 to 2022. North ... of both market revenues and unit volumes, whereas ...
(Date:2/22/2017)... Research and Markets has announced the ... Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, ... 2022" report to their offering. ... The global psoriasis drugs market ... This report provides a detailed analysis of the current ...
(Date:2/22/2017)... WASHINGTON , Feb. 22, 2017 The ... in the U.S. Senate and House of Representatives that ... Pharmacy Benefit Managers (PBMs) -- from extracting retroactive direct ... long term care (LTC) pharmacies and the Medicare program. ... Moore Capito (R-WV) and Jon Tester ...
Breaking Medicine Technology: